Accretion Nutraveda IPO

Accretion Nutraveda Limited is engaged in the manufacturing and marketing of nutraceutical, herbal, and wellness products. The company develops formulations such as dietary supplements, protein powders, herbal extracts, and functional nutrition products. Its operations are supported by an in-house manufacturing facility located in Ahmedabad, Gujarat, equipped with modern blending, packing, and quality control systems.

The company operates primarily on a B2B model, supplying products to distributors and private-label clients, while also developing its own branded wellness portfolio. It emphasizes regulatory compliance, product traceability, and quality assurance as core pillars of its operations.

Core product categories:

• Nutritional supplements

• Herbal and ayurvedic formulations

• Protein & health powders

• Capsules and tablets

• Wellness and immunity boosters

Business strengths:

• Integrated manufacturing facility

• Experienced promoter team

• Growing domestic wellness demand

• Focus on quality certifications

• Flexible product customization

India’s nutraceutical and herbal products market is growing rapidly due to rising health awareness, preventive healthcare trends, and lifestyle diseases.

Growth Drivers:

• Preventive healthcare mindset

• Aging population

• Fitness culture

• E-commerce penetration

• Government AYUSH support

📊 Growth Trend (illustrative)

Market Size
120k |            ████
90k  |        ████
60k  |    ████
30k  | ███
2024   2026   2028   2030

Promoters:

• Mr. Mayur Popatlal Sojitra

• Mr. Ankurkumar Shantilal Patel

• Mr. Paraskumar Vinubhai Parmar

• Mr. Hardik Mukundbhai Prajapati

• Mr. Harshad Nanubhai Rathod

• Mr. Vivek Ashok Kumar Patel

The promoters collectively bring expertise in pharmaceuticals, nutraceutical manufacturing, finance, and operations.

Promoter Group Entities:
Entities engaged in allied healthcare and trading activities, with no material conflict of interest.

The management team blends operational depth with financial discipline and regulatory expertise.

• Dependence on regulatory approvals (FSSAI, AYUSH)

• Raw material price volatility (herbs, extracts)

• Competition from large FMCG and pharma brands

• Product liability and quality risks

• New listing with no prior trading history

• High working capital dependency

No major criminal or tax litigation impacting business continuity.

(₹ in Lakhs)

📈 Revenue Growth

FY23 ███
FY24 █████
FY25 ████████

Operational cash flow improved with scale and margin expansion.

IPO proceeds will be used for:

1. Purchase of new machinery

2. Expansion of manufacturing capacity

3. Working capital requirements

4. General corporate purposes

Allocation:

• QIB – up to 50%

• Retail – minimum 35%

• NII – minimum 15%

Valuation is based on:

• EPS growth

• Peer comparison with nutraceutical companies

• Profitability trend

• Industry CAGR

The pricing reflects growth-stage healthcare manufacturing multiples.

• Increased equity base

• Promoters retain majority stake

• Lower leverage ratio

• Improved net worth

Includes:

• Remuneration to directors

• Purchase of raw materials from group entities

• Lease and service arrangements

All conducted at arm’s length and disclosed transparently.

Key agreements:

• Issue Agreement

• Market Making Agreement

• Registrar Agreement

• Escrow Agreement

• Underwriting Agreement

• Independent Directors appointed

• Audit, NRC & Stakeholders Committees formed

• SEBI LODR compliance

• Internal audit and controls

Management attributes growth to:

• Rising health awareness

• Expanded product portfolio

• Manufacturing scale-up

• Improved margins

• Cost discipline

Future Strategy:

• Launch new wellness products

• Strengthen private-label manufacturing

• Expand distribution

• Export opportunities

Outlook:
The company expects sustained growth aligned with India’s healthcare and nutraceutical expansion.